Science
A transformative approach that intervenes at the source of inflammation — enabled by ABX-90i, a plasmid encoding HSP90, the body's own immune master regulator.
Platform
Plasmid-based pro-resolution therapy
Mechanism
Disease
Chronic inflammation
ABX-90i
Homeostasis
Tissue repair
A roots-up approach that intervenes at the source of inflammation — restoring balance across the microbiome, gut barrier, and immune system without chronic immunosuppression.
Focus
We target a subset of chronic inflammatory bowel disease (IBD) associated with extra-intestinal manifestations (EIM) — combined diseases that are often severe and debilitating, frequently requiring complex therapeutic regimens.
Our treatment is unique, comprehensive, and promotes actual tissue repair in these complex disease combinations.
Preclinical evidence
Chronic therapeutic efficacy of ABX-90i was demonstrated in an HLA-B27/Huβ2m transgenic rat model of spontaneous enteropathic arthropathy, which closely mirrors the human disease.
Inflammatory bowel disease and an arthropathy develop spontaneously in this model. Rats were treated after intestinal disease manifested. Key disease parameters including inflammation score and hypervascularization were significantly improved by ABX-90i treatment.
Key findings